

SUPPLEMENTARY TABLE S3. EFFECT OF D-GALACTOSAMINE TREATMENT ON mRNA AND PROTEIN HALF-LIVES IN H35 CELLS

	Control	Galactosamine ^a	p-Value
mRNA half-life (h) ^b			
MAT2A	5.83 ± 2.44	6.25 ± 1.78	0.79
MAT2B	6.76 ± 1.90	12.53 ± 2.44 ^c	0.02
SAHH	67.36 ± 29.88	9.77 ± 0.70 ^c	0.02
MTR	12.48 ± 4.16	13.49 ± 10.22	0.86
BHMT	82.53 ± 77.0	9.58 ± 10.14	0.24
GCLI	4.00 ± 0.56	7.70 ± 2.06 ^c	0.02
GCLm	11.23 ± 4.82	39.80 ± 1.88 ^c	0.003
Protein half-life (h) ^d			
BHMT	16.34 ± 6.25	44.20 ± 20.47 ^c	0.05
SAHH	14.62 ± 3.22	34.85 ± 15.27 ^c	0.01

H35 cells were treated with PBS or 10 mM D-galactosamine (^a) for 48 h before addition of 5 µg/ml actinomycin D (^b) or 20 µg/ml cycloheximide (^d) in the absence of serum to determine mRNA or protein half-lives, respectively. The results shown are the average of three experiments carried out in triplicate (mean ± SD) and were considered significant when $p \leq 0.05$ (^c).

GCLm, γ -glutamylcysteine synthetase modifier; GCLI, γ -glutamylcysteine synthetase ligase; MTR, methionine synthase; SAHH, S-adenosylhomocysteine hydrolase.